Karyopharm Therapeutics Inc.
KPTI
$7.46
$1.1518.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.43% | 57.27% | 46.60% | 37.41% | 36.50% |
| Total Depreciation and Amortization | -3.90% | 2.46% | -35.85% | -40.64% | -50.15% |
| Total Amortization of Deferred Charges | 396.15% | 963.82% | 682.43% | 424.04% | 152.11% |
| Total Other Non-Cash Items | 56.69% | -549.22% | -426.34% | -345.93% | -297.40% |
| Change in Net Operating Assets | 3,470.34% | -13.27% | -100.96% | -50.97% | -104.43% |
| Cash from Operations | 21.02% | -4.43% | -37.49% | -19.09% | -30.57% |
| Capital Expenditure | 127.18% | 127.18% | -- | -- | -400.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.72% | 42.11% | 1,104.22% | 227.92% | 242.82% |
| Cash from Investing | -39.54% | 42.64% | 1,102.43% | 227.69% | 242.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00% | 29.18% | 29.18% | -99.34% | -99.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -206.44% | -- | -- | -- | -- |
| Cash from Financing | -97.49% | 3,605.16% | 3,605.16% | -73.69% | -74.63% |
| Foreign Exchange rate Adjustments | 190.00% | 300.00% | 67.65% | 3,166.67% | 166.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,511.25% | 114.28% | 111.50% | 200.39% | 249.84% |